These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 32058070)
21. Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications. Turpin D; Furudoi A; Parrens M; Blanco P; Viallard JF; Duluc D Clin Immunol; 2018 Dec; 197():130-138. PubMed ID: 30219667 [TBL] [Abstract][Full Text] [Related]
22. Vedolizumab Therapy in Refractory Enteropathy Associated With CVID. Johnson D; Lee G; Weber F ACG Case Rep J; 2022 Jan; 9(1):e00721. PubMed ID: 34977264 [TBL] [Abstract][Full Text] [Related]
23. Common variable immunodeficiency: association between memory B cells and lung diseases. Detková D; de Gracia J; Lopes-da-Silva S; Vendrell M; Alvarez A; Guarner L; Vidaller A; Rodrigo MJ; Caragol I; Espanol T; Hernández M Chest; 2007 Jun; 131(6):1883-9. PubMed ID: 17400689 [TBL] [Abstract][Full Text] [Related]
24. Common variable immunodeficiency (CVID) presenting with malabsorption due to giardiasis. Onbaşi K; Günşar F; Sin AZ; Ardeniz O; Kokuludağ A; Sebik F Turk J Gastroenterol; 2005 Jun; 16(2):111-3. PubMed ID: 16252205 [TBL] [Abstract][Full Text] [Related]
25. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Grandinetti T; Biedermann L; Bussmann C; Straumann A; Hruz P Dig Dis Sci; 2019 Aug; 64(8):2231-2241. PubMed ID: 30982212 [TBL] [Abstract][Full Text] [Related]
27. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Chua I; Standish R; Lear S; Harbord M; Eren E; Raeiszadeh M; Workman S; Webster D Clin Exp Immunol; 2007 Nov; 150(2):306-11. PubMed ID: 17822445 [TBL] [Abstract][Full Text] [Related]
28. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Malphettes M; Gérard L; Carmagnat M; Mouillot G; Vince N; Boutboul D; Bérezné A; Nove-Josserand R; Lemoing V; Tetu L; Viallard JF; Bonnotte B; Pavic M; Haroche J; Larroche C; Brouet JC; Fermand JP; Rabian C; Fieschi C; Oksenhendler E; Clin Infect Dis; 2009 Nov; 49(9):1329-38. PubMed ID: 19807277 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. Van den Berghe N; Verstockt B; Tops S; Ferrante M; Vermeire S; Gils A J Gastroenterol Hepatol; 2019 Jul; 34(7):1175-1181. PubMed ID: 30589948 [TBL] [Abstract][Full Text] [Related]